a New glucuronosyldiacylglycerol (GlcADG) analogues based on a 2-O-β-D-glucopyranosyl-sn-glycerol scaffold and carrying one or two acyl chains of different lengths have been synthesized as phosphatidylinositol 3-phosphate (PI3P) mimics targeting the protein kinase Akt. The Akt inhibitory effect of the prepared compounds was assayed using an in vitro kinase assay. The antiproliferative activity of the compounds was tested in the human ovarian carcinoma IGROV-1 cell line in which we found that two of them could inhibit proliferation, in keeping with the target inhibitory effect.
Introduction
Glucuronosyldiacylglycerols (GlcADGs, Fig. 1 ) are unusual acidic glycoglycerolipids found in bacteria, 1 fungi, 2 algae 3 and in some higher plants such as Arabidopsis thaliana and rice, 4 and only very recently their first synthesis has been reported. 5 Their presence in these photosynthetic organisms seems to be related to conditions of reduced phosphorous availability in which they replace phospholipids for their biological functions. 4, 6 GlcADGs participate in this lipid remodelling as the better-known anionic sulfolipids, sulfoquinovosyldiacylglycerols (SQDGs, Fig. 1 ), 7, 8 sharing also the same biosynthetic pathway which requires a common SQDG synthase. 4 In contrast to
GlcADGs, in the last few years both natural and synthetic sulfoquinovosylacylglycerols have been tested for their antitumor, antiviral, anti-inflammatory, immunosuppressive and other bioactivities. [9] [10] [11] [12] [13] This prompted us to prepare some SQDG analogues ( Fig. 1 ) based on 2-O-β-D-glucosylglycerol, which were tested as inhibitors of tumor-promoters in cancer prevention studies. 14a,15 These unnatural sulfolipids, similar to other glucose-based compounds, 16 display a structure which can be related to that of 3-phosphorylated phosphatidylinositol (PI3P, Fig. 1 ), one of the natural phospholipids involved in the regulation of specific lipid-binding domains (e.g. PH, FYVE or PX) in phosphatidylinositol-3-kinase (PI3K) effector proteins.
17a-d
Thus they are currently investigated as potential inhibitors of protein kinase B (PKB or Akt), 18 a kinase involved in sustaining multiple aggressive features of tumor cells such as invasion capability and reduced sensitivity to antitumor agents.
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PI3P and the other 3-phosphorylated phosphatidylinositols, i.e. PI(3,4,5)P 3 and PI(3,4)P 2 , are generated by PI3K and, at the plasma membrane, they can bind the pleckstrin homology (PH) domain promoting kinase activation.
17a,20 Many proteins with the PH domain are known, but only a few of them are regulated by the direct binding of 3-phosphoinositides. 17a For this reason, even if different types of small molecules have been synthesized as Akt inhibitors (e.g. ATP mimetics and allosteric inhibitors), PH binders (such as perifosine, 3-DPI and 3-DPIEL) are thought as more selective potential Akt inhibitors. 19, 21, 22 Here we describe the synthesis of the new glucuronosyldiacylglycerol (GlcADG) analogues 1a,b and 2a,b, carrying acyl chains which differ in length and number ( Fig. 1) as PI3P analogues that could target the Akt pleckstrin homology domain. They maintain the same 2-O-β-D-glucopyranosyl-sn-glycerol scaffold of SQDG analogues but a diverse anionic group is installed at position 6 of the sugar moiety (COO − vs. SO 3 − ) for interaction with the PI3P binding pocket of the PH domain, which is characterized by positively charged residues. 22 At the same time the glucuronides 3a,b ( Fig. 1 ) have been prepared as simplified anionic models for binding the PH domain. The biological activity of selected compounds is also presented as inhibitory activity against Akt, both in an isolated enzyme system and in an ovarian carcinoma cell line.
Results and discussion
Chemistry Synthesis of monoesters 1a,b. Compounds 1a,b were efficiently prepared starting from the known 2-O-(2′,3′,4′,6′-tetra-O-acetyl-β-D-glucopyranosyl)-sn-glycerol 23a,b (Scheme 1).
Its Pseudomonas cepacia lipase (LPS) mediated transesterification in an organic solvent, by means of a procedure already used for similar substrates employing 2,2,2-trifluoroethyl (TFE) esters as acyl carriers, 24 allowing selective introduction of the desired acyl chain (octadecanoyl or decanoyl) at C-1 of the snglycerol moiety in good yields. The configurations of the obtained 4a,b were confirmed by chemical correlation with known compounds 24 (vide infra). After conventional tritylation of the remaining primary free hydroxyl, the obtained fully protected glucosylglycerols 5a,b were converted with reasonable yields into the fully deacetylated compounds 6a,b by treatment with hydrazine hydrate in aqueous ethanol for selective removal of the sugar acetyls. 25 Selective TEMPO oxidation of the glucose primary hydroxyl group yielded 7a,b which were finally transformed into the desired compounds 1a,b by treatment with an acidic resin in dichloromethane. Configuration assignment of compounds 4a,b. Compound 4a was transformed into the 3-O-acetyl derivative by acetic anhydride/pyridine treatment. The obtained compound was identical to the known 1-O-octadecanoyl-3-O-acetyl-2-O-(2′,3′,4′,6′-tetra-O-acetyl-β-D-glucopyranosyl)-sn-glycerol, 24 confirming the 2S configuration of compound 4a. As the enzymatic transesterifications employed to obtain the monoesters 4a and 4b differed just in the acyl carrier used, only the configuration of compound 4a was assigned, assuming the same 2S configuration for compound 4b also.
Synthesis of diesters 2a,b. commercial octyl β-D-glucopyranoside, respectively.
Cell free evaluation of Akt inhibition
The prepared glucuronides, with the exception of compound 2a that was not soluble in DMSO, were tested for in vitro inhibitory activity against Akt (Akt1), using an in vitro ELISA kinase assay. Fig. 2 shows the effects of compounds 1a-b, 2b, 3a-b, tested at five different (1, 10, 50, 100 and 500 µM) concentrations compared to the alkylphospholipids (ALPs) miltefosine (general inhibitor of the PI3K/Akt pathway) and perifosine (Akt inhibitor targeting the PH domain) 29 and the surfactant sodium dodecyl sulfate (SDS). The results show that the Akt1 activity is poorly influenced by compound 3b, while the other compounds showed a concentration-dependent inhibitory effect, 1a and 2b being the most potent inhibitors of Akt1 activity (IC 50 a concentration-dependent inhibition of Akt1, however they displayed only slight efficacy, even at the maximum concentration: 24% and 39%, respectively. The IC 50 values (Table 1) and the maximal efficacy indicated that the effect is higher for long than for short acyl chains (1a vs. 1b and 3a vs. 3b) and for the presence of a second acyl chain (1b vs. 2b, Table 1 ). These results are in agreement with other data obtained by our group. 18 The data obtained (Table 1 and Fig. 2 ) for miltefosine as well as SDS did not exhibit any significant inhibition of Akt in the ELISA test (only a very weak inhibition was observed at very high concentrations, i.e. 500 µM). In contrast, perifosine displayed a significant inhibition with an IC 50 value of about 40 µM, thus suggesting a specificity for the effect induced by glucuronides 1a and 2b and a potency that is comparable with that of perifosine.
Cellular studies
The antiproliferative activity of the glucuronide compounds was examined in the IGROV-1 ovarian carcinoma cell line which is characterized by heterozygous mutation (Het c.955_958delACTT) of the dual-specificity phosphatase PTEN, a negative regulator of Akt. A 72 h exposure to the compounds resulted in a concentration-dependent inhibition of IGROV-1 cell growth for three of the novel glucuronides (Fig. 3) . In particular, the inhibitory effect was evident for compounds 1a and 2b. In fact, the IC 50 values (±SD) were 49.0 ± 7.6 and 156.7 ± 23.0 (SD) μM, respectively. The 3a and 3b compounds induced a slight inhibition of IGROV-1 cell growth after a 72 h exposure only when a concentration of 300 μM was used. A modest inhibition of proliferation was also observed when cells were exposed to the 1b compound, the IC 50 value being around 300 μM. Since the 3a and 3b compounds do not contain glycerol in their structure, such data suggest that the presence of glycerol might facilitate growth inhibition (1b vs. 3a). Moreover, long chains seem to enhance the activity because the 1a compound carries a longer chain than 1b.
Further effort is required to optimize the growth inhibition properties of this class of compounds. Indeed, an analysis of inhibition of cell growth in cells exposed for 24 h to the studied compounds in a serum-free medium indicated an increased potency for the two active compounds. Under these conditions, the IC 50 values (±SD) of compounds 1a and 2b were 3.35 ± 0.35 and 9.40 ± 5.0 μM, respectively. This evidence raises the possibility that binding of the compounds to serum components can reduce their cellular uptake or affect their stability.
To confirm the influence of the serum presence in a medium on cellular sensitivity towards Akt inhibitors, we also tested the sensitivity of IGROV-1 cells towards perifosine in the presence and absence of serum in the medium (Table 2 ). Under our experimental conditions, we found that the growth inhibitory effect of the compound was favored in a serum-free medium, thus implying that serum affects the stability of perifosine. However, for perifosine a 2.8 fold increase in the antiproliferative activity was observed upon incubation in a serumfree medium; the fold-change for the novel compounds was higher, implying that they might be less stable or less prone to accumulate in the cells than perifosine in the presence of serum.
Conclusions
New glucuronosyldiacylglycerols were prepared and their inhibitory activity against Akt, both in an isolated enzyme system and in an ovarian carcinoma cell line, was tested.
The two compounds exhibiting the best target inhibition activity in a cell-free assay, i.e. compounds 1a and 2b, were found to be endowed with antiproliferative activity in ovarian carcinoma cells. Although inhibition of proliferation was observed, further efforts are needed to increase the potency of the compounds in in vitro cultured cells. Overall, our data, by showing a clear modulation of Akt inhibition in relation to chain length and number, and also to the presence of glycerol in cell experiments, provide insights into the understanding of structural features needed to achieve Akt inhibition.
Experimental

Chemical procedures
Materials and equipment. Pseudomonas cepacia lipase (LPS, lipase PS, specific activity 30.5 triacetin units per mg solid), from Amano Pharmaceutical Co. (Mitsubishi Italia), was supported on Celite. 24 
Chemistry
Synthesis of monoesters 1a and 1b suspension was filtered to remove the enzyme which was washed with pyridine and methanol. The solvent was evaporated under vacuum and the crude compound was purified by flash chromatography (hexane-EtOAc from 90 : 10 to 20 : 80, With the same procedure, starting from 4b (0.51 g, 0.88 and H-1b), 5.04 (d, 1H, J 1′,2′ = 7.7 Hz, H-1′), 7.23 (dd, 3H, J = 7.3 Hz, Ph), 7.32 (dd, 6H, J = 7.4 Hz, Ph), 7.64 (d, 6H, J = 7.8 Hz, Ph); 13 With the same procedure, starting from 6b (0.21 g, 0.32 mmol), 
Configuration assignment of compound 4a
Compound 4a (0.027 g, 0.04 mmol) was dissolved in dry pyridine (1 mL) and acetic anhydride (0.5 g, 4.9 mmol) was added. The reaction was stirred at room temperature and stopped after 3 hours (TLC, hexane-EtOAc 60 : 40 v/v). After the usual work-up the crude compound was purified by flash chromatography ( Synthesis of diesters 2a and 2b 
Akt inhibition assays
Akt1 ELISA activity assay. The inhibitory activity of compounds 1a-b, 2b, 3a-b, miltefosine (Sigma), perifosine (Sigma) and SDS (Sigma) was tested employing the CycLex AKT/PKB kinase Assay/Inhibitor Screening Kit (CycLex, Eppendorf, Milano, Italy). Plates were pre-coated with "AKTide-2T" which can be efficiently phosphorylated by Akt1. The detector antibody specifically detects the phosphorylated "AKTide-2T". Particularly, to perform the test, samples 1a-b, 2b, 3a-b and SDS were dissolved in DMSO (note that 2a was insoluble in this solvent), and miltefosine and perifosine in water. The prepared solutions were then diluted in kinase buffer to a final concentration of 500, 100, 50, 10 and 1 µM, respectively. Compounds were added together with the constitutive active form of human Akt1 (25 m units per well), and allowed to phosphorylate the bound substrate following the addiction of Mg 2+ and ATP. The amount of phosphorylated substrate was measured by binding it with the horseradish peroxidase conjugate of an anti-phospho-AKTide-2T monoclonal antibody, which then catalyzes the conversion of the chromogenic substrate tetramethylbenzidine from the colourless reduced form to the yellow oxidized product, after the addition of the stopping reagent. The absorbance of the resulting solution is determined spectrophotometrically at λ = 450 nm, and it is related to Akt1 activity in the tested solution. Staurosporine (SigmaAldrich, Milano, Italy) at the final concentration of 1 µM was employed as the "inhibitor control" as indicated in the assay protocol. Each experiment was performed in triplicate.
Cellular studies
Compound preparation. Perifosine was dissolved in H 2 O at 20 mM. All tested compounds were easily dissolved in 100% DMSO at 50 mM. Cell culture and cell growth assay: the human ovarian carcinoma IGROV-1 cell line 30 was grown in RPMI-1640 medium supplemented with 10% fetal bovine serum at 37°C under 5% CO 2 atmosphere. For cell growth inhibition assays, cells were plated in 12-well plates at 10 000 cells cm −2 in a complete medium. The day after seeding, cells were exposed to the solvent (DMSO) or to different concentrations of the novel compounds for 72 h. For tests in a serumfree medium, the day after seeding complete medium was substituted with a serum-free medium and the cells were exposed to the compounds. Twenty-four hours later the drug-containing medium was replaced with a complete medium. Cells were harvested using trypsin and counted 96 h after seeding using a Coulter Counter (Z1, Beckman Coulter). Each experiment was performed three times. The percentages of inhibition in drug-treated versus solvent-treated samples are reported in dose-response curves. IC 50 represents the drug concentration inhibiting growth by 50%.
